Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Cetuximab in Metastatic KRAS Wild-Type Colorectal Cancer
NCT00954876Phase 2Withdrawn
- Sponsor
- Translational Genomics Research Institute
- Start
- Aug 2009
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in colorectal cancer (metastatic) (mCRC), sponsored by Translational Genomics Research Institute. Planned start Aug 2009; status: withdrawn.
02
Drugs
KL-140
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00954876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00954876.